JP2015508648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508648A5 JP2015508648A5 JP2014557308A JP2014557308A JP2015508648A5 JP 2015508648 A5 JP2015508648 A5 JP 2015508648A5 JP 2014557308 A JP2014557308 A JP 2014557308A JP 2014557308 A JP2014557308 A JP 2014557308A JP 2015508648 A5 JP2015508648 A5 JP 2015508648A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- polypeptide
- antigen
- particle
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261599746P | 2012-02-16 | 2012-02-16 | |
| US61/599,746 | 2012-02-16 | ||
| PCT/JP2013/054422 WO2013122262A1 (en) | 2012-02-16 | 2013-02-15 | Virus like particle composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017202679A Division JP2018064556A (ja) | 2012-02-16 | 2017-10-19 | ウイルス様粒子組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508648A JP2015508648A (ja) | 2015-03-23 |
| JP2015508648A5 true JP2015508648A5 (enExample) | 2016-03-24 |
| JP6306518B2 JP6306518B2 (ja) | 2018-04-04 |
Family
ID=48984367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557308A Active JP6306518B2 (ja) | 2012-02-16 | 2013-02-15 | ウイルス様粒子組成物 |
| JP2017202679A Pending JP2018064556A (ja) | 2012-02-16 | 2017-10-19 | ウイルス様粒子組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017202679A Pending JP2018064556A (ja) | 2012-02-16 | 2017-10-19 | ウイルス様粒子組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9249191B2 (enExample) |
| EP (1) | EP2814847B1 (enExample) |
| JP (2) | JP6306518B2 (enExample) |
| KR (1) | KR102181258B1 (enExample) |
| CN (2) | CN104220462A (enExample) |
| AP (1) | AP2014007864A0 (enExample) |
| AR (1) | AR092796A1 (enExample) |
| AU (1) | AU2013221187B9 (enExample) |
| BR (1) | BR112014020052B8 (enExample) |
| CA (1) | CA2863695C (enExample) |
| MX (1) | MX357202B (enExample) |
| NZ (2) | NZ717682A (enExample) |
| RU (1) | RU2705301C2 (enExample) |
| SG (2) | SG10201606635SA (enExample) |
| TW (1) | TWI695844B (enExample) |
| WO (1) | WO2013122262A1 (enExample) |
| ZA (1) | ZA201405694B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ717682A (en) * | 2012-02-16 | 2017-10-27 | Vlp Therapeutics Llc | Virus like particle composition |
| EP2712871A1 (en) * | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| CN105431535A (zh) | 2013-06-03 | 2016-03-23 | Vlp治疗有限责任公司 | 疟疾疫苗 |
| TWI676636B (zh) * | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| CN106795513B (zh) * | 2014-08-08 | 2021-06-11 | Vlp治疗公司 | 包含修饰的包膜蛋白e3的病毒样颗粒 |
| CN106687590B (zh) | 2014-09-11 | 2021-08-03 | Vlp治疗公司 | 黄热病毒病毒样颗粒 |
| GB2535753A (en) * | 2015-02-26 | 2016-08-31 | The Native Antigen Company | Particles comprising fusion proteins |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| CN105176936B (zh) * | 2015-10-23 | 2019-01-11 | 中国科学院武汉物理与数学研究所 | 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用 |
| JP6904959B2 (ja) * | 2016-01-04 | 2021-07-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 結合エピトープを含有する融合タンパク質を封入する粒子 |
| CN109803677A (zh) * | 2016-07-15 | 2019-05-24 | 埃特彼塞斯公司 | 用于α病毒疫苗接种的组合物和方法 |
| KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| WO2018161092A1 (en) * | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| JP7653013B2 (ja) | 2018-01-04 | 2025-03-28 | アイコニック セラピューティクス リミテッド ライアビリティ カンパニー | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| JP2021512966A (ja) * | 2018-02-07 | 2021-05-20 | イミュジーン、リミテッドＩｍｕｇｅｎｅ Ｌｉｍｉｔｅｄ | ワクチン組成物およびその使用 |
| WO2019156223A1 (ja) * | 2018-02-09 | 2019-08-15 | 国立大学法人大阪大学 | チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途 |
| JP6906207B2 (ja) * | 2018-02-09 | 2021-07-21 | 国立大学法人大阪大学 | チクングニアウイルス検出用免疫クロマト分析装置 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| CN112852852B (zh) * | 2019-11-27 | 2023-07-25 | 中国医学科学院医学生物学研究所 | 一种ox40抗原表位重组病毒样颗粒及其制备方法和应用 |
| EP4135847A4 (en) | 2020-04-17 | 2024-05-15 | VLP Therapeutics, Inc. | Coronavirus vaccine |
| WO2021215952A1 (ru) | 2020-04-24 | 2021-10-28 | Общество С Ограниченной Ответственностью "Индженик" | Способ получения частиц бактериофагов семейства levivirus |
| WO2021221127A1 (en) | 2020-04-30 | 2021-11-04 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
| WO2024015890A1 (en) | 2022-07-13 | 2024-01-18 | Modernatx, Inc. | Norovirus mrna vaccines |
| WO2025029700A1 (en) | 2023-07-28 | 2025-02-06 | Modernatx, Inc. | Vlp enteroviral vaccines |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| CA2123612C (en) | 1991-11-16 | 2002-06-25 | Michel De Wilde | Hybrid protein between cs from plasmodium and h bsag |
| US5580773A (en) * | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
| JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| AU716466B2 (en) * | 1995-09-27 | 2000-02-24 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
| WO1999041383A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US20110262389A1 (en) * | 2001-02-13 | 2011-10-27 | Mosca Joseph D | Tumor-derived Biological Antigen Presenting Particles |
| WO2002096939A2 (en) | 2001-05-30 | 2002-12-05 | Transgene S.A. | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| US20050031592A1 (en) | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
| MXPA05012754A (es) | 2003-05-29 | 2006-05-17 | Army Medical Res Inst For I | Vacunas virales atenuadas vivas para virus de encefalitis equina oriental. |
| SI1629004T1 (sl) * | 2003-06-05 | 2008-12-31 | Wyeth Corp | Imunogeni sestavki, ki vsebujejo vektorski replikon virusa venezuelskega konjskega encefalitisa in antigen za protein paramiksovirusa |
| EP1758925A4 (en) | 2003-12-01 | 2009-04-08 | Dow Global Technologies Inc | PRODUCTION OF A RECOMBINANT ICOSAHEDRIC VIRUS LIKE PARTICLE |
| CN101023103A (zh) * | 2004-09-21 | 2007-08-22 | 赛托斯生物技术公司 | 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒 |
| MX2007003171A (es) * | 2004-09-21 | 2007-05-23 | Cytos Biotechnology Ag | Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico. |
| ES2371175T3 (es) | 2004-10-14 | 2011-12-28 | Crucell Holland B.V. | Vacunas de sensibilización/refuerzo de malaria. |
| WO2006088229A1 (ja) | 2005-02-16 | 2006-08-24 | The Circle For The Promotion Of Science And Engineering | 改変されたウイルスカプシドタンパク質及びその使用 |
| KR101510065B1 (ko) | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| EP2468765B1 (en) | 2006-03-03 | 2015-04-22 | ONO Pharmaceutical Co., Ltd. | Tetramer of extracellular domain of PD-L1 |
| US20100120092A1 (en) | 2006-08-30 | 2010-05-13 | Hepgenics Pty Ltd. | Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| WO2009079185A2 (en) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
| SG171828A1 (en) * | 2008-11-26 | 2011-07-28 | Us Gov Health & Human Serv | Virus like particle compositions and methods of use |
| ES2752323T3 (es) | 2009-09-18 | 2020-04-06 | Fraunhofer Usa Inc | Partículas de tipo virus que comprenden proteínas diana fusionadas a proteínas de revestimiento de virus vegetales |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| WO2012106356A2 (en) | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| AU2012269907B2 (en) | 2011-06-17 | 2017-05-18 | Bharat Biotech International Limited | Vaccine composition comprising an inactivated chikungunya virus strain |
| CN102321639B (zh) * | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
| BR112014009887A2 (pt) | 2011-10-25 | 2017-04-25 | Florida Gulf Coast Univ | vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue |
| NZ717682A (en) * | 2012-02-16 | 2017-10-27 | Vlp Therapeutics Llc | Virus like particle composition |
| US9821050B2 (en) | 2012-04-02 | 2017-11-21 | The University Of North Carolina At Chapel Hill | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions |
| PT2850431T (pt) | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
| CN105431535A (zh) | 2013-06-03 | 2016-03-23 | Vlp治疗有限责任公司 | 疟疾疫苗 |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| US10060924B2 (en) | 2014-03-18 | 2018-08-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
| CN106795513B (zh) | 2014-08-08 | 2021-06-11 | Vlp治疗公司 | 包含修饰的包膜蛋白e3的病毒样颗粒 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
| KR102713707B1 (ko) | 2014-12-31 | 2024-10-04 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 신규 다가 나노입자 기반 백신 |
| JPWO2016199936A1 (ja) | 2015-06-12 | 2018-04-05 | 国立大学法人三重大学 | ヒトパラインフルエンザ２型ウイルスベクター及びワクチン |
| WO2016210127A1 (en) | 2015-06-25 | 2016-12-29 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
| JP6896700B2 (ja) | 2015-07-16 | 2021-06-30 | バハラ バイオテック インターナショナル リミテッド | ワクチン組成物 |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| CN106085974B (zh) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | 一种寨卡病毒假病毒颗粒及其制备方法 |
-
2013
- 2013-02-15 NZ NZ717682A patent/NZ717682A/en unknown
- 2013-02-15 SG SG10201606635SA patent/SG10201606635SA/en unknown
- 2013-02-15 AU AU2013221187A patent/AU2013221187B9/en active Active
- 2013-02-15 RU RU2014133527A patent/RU2705301C2/ru active
- 2013-02-15 SG SG11201404711WA patent/SG11201404711WA/en unknown
- 2013-02-15 CN CN201380020165.9A patent/CN104220462A/zh active Pending
- 2013-02-15 US US13/768,801 patent/US9249191B2/en active Active
- 2013-02-15 EP EP13749307.8A patent/EP2814847B1/en active Active
- 2013-02-15 KR KR1020147025267A patent/KR102181258B1/ko active Active
- 2013-02-15 CN CN202110434277.5A patent/CN113248626A/zh active Pending
- 2013-02-15 MX MX2014009916A patent/MX357202B/es active IP Right Grant
- 2013-02-15 AR ARP130100474A patent/AR092796A1/es not_active Application Discontinuation
- 2013-02-15 WO PCT/JP2013/054422 patent/WO2013122262A1/en not_active Ceased
- 2013-02-15 BR BR112014020052A patent/BR112014020052B8/pt active IP Right Grant
- 2013-02-15 JP JP2014557308A patent/JP6306518B2/ja active Active
- 2013-02-15 NZ NZ628206A patent/NZ628206A/en not_active IP Right Cessation
- 2013-02-15 AP AP2014007864A patent/AP2014007864A0/xx unknown
- 2013-02-15 CA CA2863695A patent/CA2863695C/en active Active
- 2013-02-18 TW TW102105497A patent/TWI695844B/zh active
-
2014
- 2014-07-31 ZA ZA2014/05694A patent/ZA201405694B/en unknown
-
2015
- 2015-12-08 US US14/962,805 patent/US11345726B2/en active Active
-
2017
- 2017-10-19 JP JP2017202679A patent/JP2018064556A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521539A5 (enExample) | ||
| RU2014133527A (ru) | Композиция вирусоподобных частиц | |
| EP3177720B1 (en) | Virus like particle comprising modified envelope protein e3 | |
| US9637532B2 (en) | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen | |
| JP7788787B2 (ja) | 遺伝子発現増強のための組成物および方法 | |
| McCormick et al. | Genetically engineered Tobacco mosaic virus as nanoparticle vaccines | |
| US10385101B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| TW201529605A (zh) | 瘧疾疫苗 | |
| Rice | Alphavirus-based expression systems | |
| CN107074968B (zh) | 疫苗 | |
| CN101502657A (zh) | 噬菌体与EB病毒的gp350蛋白融合载体疫苗的构建方法 | |
| TH112180A (th) | โปรตีนผสมชนิดใหม่ ๆ และการใช้โปรตีนเหล่านี้เพื่อการเตรียมวัคซีนต้านไวรัสตับอักเสบ ซี | |
| OA17353A (en) | Virus like particle composition. |